Damora Therapeutics is trading 5.1% down today at $27.08 on profit-taking and price normalization following a volatile two-week rally.
- The reversal comes despite a lack of fresh company-specific news today, as the stock pulls back from recent sharp gains.
- Broader risk-off sentiment across growth and biotechnology sectors is adding further downward pressure to the share price.
- Recent catalysts for the stock included July 1 inducement grants and several new analyst initiations.